 |
Prospector
Profile
118-02
|
| |
| AVANIR Pharmaceuticals |
NAICS |
325412 |
| 101 Enterprise Suite 300,
Aliso Viejo, CA 92656 |
Description |
Pharmaceuticals Mfg. |
| (949) 389-6700 |
Employees |
25 |
| http://www.avanir.com/ |
Revenue |
(mil) |
0.0720 |
| |
Income |
(mil) |
-20.9330 |
| |
Assets |
(mil) |
39.0950 |
| |
Liability |
(mil) |
32.0650 |
| |
(for the year ended 2007-09-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
AVANIR Pharmaceuticals had a net loss of $20,933,453 for the year ended September 30, 2007, which is lower than the net losses of $62,552,814 and $30,606,564 reported for the years ended September 30, 2006 and 2005, respectively. The Company had revenues of $72,000 for the year ended September 30, 2006, which is higher than the revenues of $18,270 and $17,400 reported for the 2006 and 2005 fiscal years, respectively. The Company's balance sheet showed an accumulated deficit of $238,498,733 and only $7,030,234 in stockholders' equity.
|
| |
|
Intellectual Property:
As of September 30, 2007, the Company owned or had the rights to 183 issued patents (42 U.S. and 141 foreign) and 271 pending applications (35 U.S. and 236 foreign). Patents and patent applications owned by the Company include Zenvia; docosanol-related products and technologies; Xenerex antibody technologies; selective cytokine inhibitor; MIF inhibitor technology and reverse cholesterol transport enhancer. [SEC Filing 10-K 12-21-07]
|
| |
|
Description:
AVANIR Pharmaceuticals focuses on treatments of chronic diseases. The Company is developing Neurodex for the treatment of pseudobulbar affect and chronic diabetic neuropathic pain.
|
| |
|
Officers:
Eric K. Brandt (Pres. & CEO); Michael J. Puntoriero (SVP & CFO); Charles A. Mathews (Dir.); Stephen G. Austin (Dir.); David J. Mazzo (Dir.); Dennis G. Podlesak (Dir.); Jonathan T. Silverstein (Dir.); Paul G. Thomas (Dir.); Craig A. Wheeler (Dir.); Scott M. Whitcup (Dir.)
|
| |
|
Auditor:
Deloitte & Touche LLP
|
| |
|
Securities:
Common Stock-Symbol AVNR; NasdaqGM;
43,121,858 common shares outstanding as of December 7, 2007.
9.5% equipment loan due April 2008;
10.43% equipment loan due February 2009; 10.17% equipment loan due January 2009.
|
| |
| |
| |
| return to main page |
|
|
